6533b837fe1ef96bd12a1ef0
RESEARCH PRODUCT
Should reduction of increased short‐term blood pressure variability be a target of antihypertensive therapy?
Alessandra SorceMaria Giovanna VarioGiuseppe MulèMarta GiambroneSantina Cottonesubject
Blood pressure variabilityIntervention trialsmedicine.medical_specialtyAmbulatory blood pressureEndocrinology Diabetes and MetabolismBlood Pressure030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicineInternal MedicineHypertension generalHumansMedicine030212 general & internal medicineAntihypertensive Agentsbusiness.industryLeft ventricular hypertrophy (LVH) hypertensionBlood Pressure DeterminationAmbulatory blood pressureBlood Pressure Monitoring Ambulatoryhypertension—generalTarget organ damageOrgan damageAntihypertensive AgentBlood pressureHypertensionCommentaryCardiologyCardiology and Cardiovascular MedicinebusinessHumandescription
Abstract It has long been known that blood pressure (BP) is characterized by marked short‐term fluctuations occurring within a 24‐h period and also by long‐term oscillations occurring over more prolonged periods of time. An increased short‐term blood pressure variability (BPV) appears to importantly contribute to target organ damage and to the enhanced cardiovascular risk of hypertensive patients, over and above the effect of an increase in mean BP levels. Reducing 24‐h mean BP is the main aim of antihypertensive therapy, but initial data are available that additional cardiovascular protection can be achieved by reducing BPV. However, to definitively prove the prognostic role of short‐term BPV and the need for its control by treatment, evidence is still needed from intervention trials aimed at demonstrating that by reducing BPV through administration of antihypertensive drugs, a reduction in organ damage and in the rate of cardiovascular events can be obtained.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-02-04 | The Journal of Clinical Hypertension |